Keryx Biopharma (KERX) Reports Q1 Loss of 13c/Share, Misses by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Financial Fact:
Total research and development: 8.67M
Today's EPS Names:
OMID, SICP, SCKT, More
Financial Fact:
Total research and development: 8.67M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).
For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.
For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robinhood shares fall on Q3 revenue miss even as EPS beats
- Highwoods Properties (HIW) Tops Q3 EPS by 7c
- National Bank Holdings (NBHC) Misses Q3 EPS by 102c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
